Abstract
SARS-CoV-2, the virus responsible for COVID-19, is causing a devastating worldwide pandemic, and there is a pressing need to understand the development, specificity, and neutralizing potency of humoral immune responses during acute infection. We report a cross-sectional study of antibody responses to the receptor-binding domain (RBD) of the spike protein and virus neutralization activity in a cohort of 44 hospitalized COVID-19 patients. RBD-specific IgG responses are detectable in all patients 6 days after PCR confirmation. Isotype switching to IgG occurs rapidly, primarily to IgG1 and IgG3. Using a clinical SARS-CoV-2 isolate, neutralizing antibody titers are detectable in all patients by 6 days after PCR confirmation and correlate with RBD-specific binding IgG titers. The RBD-specific binding data were further validated in a clinical setting with 231 PCR-confirmed COVID-19 patient samples. These findings have implications for understanding protective immunity against SARS-CoV-2, therapeutic use of immune plasma, and development of much-needed vaccines.
Original language | English (US) |
---|---|
Article number | 100040 |
Journal | Cell Reports Medicine |
Volume | 1 |
Issue number | 3 |
DOIs | |
State | Published - Jun 23 2020 |
Keywords
- COVID-19
- SARS-CoV-2
- coronavirus
- humoral immune response
- neutralizing antibody
- protective immunity
- receptor-binding protein
- serology test
- spike protein
ASJC Scopus subject areas
- General Biochemistry, Genetics and Molecular Biology